Breaking News Instant updates and real-time market news.

AMGN

Amgen

$203.49

1.17 (0.58%)

, CHRS

Coherus Biosciences

$10.91

0.15 (1.39%)

09:50
11/30/18
11/30
09:50
11/30/18
09:50

Coherus Biosciences announces 340B prime vendor contract agreement with Apexus

Coherus BioSciences (CHRS) announced that the company has executed a 340B prime vendor program contract agreement with Apexus. Apexus is a recognized leader in the ambulatory hospital outpatient setting and the Health Resources and Services Administration prime vendor for the 340B drug pricing program, of which UDENYCA is a part. Apexus contracts with more than 95% of the 340B eligible covered entities, and the 340B channel represents about 35% of the Neulasta units sold in the U.S. In addition to entering into a UDENYCA contract agreement with Apexus, Coherus BioSciences has received Q-Code medical billing status for UDENYCA from the Centers for Medicare and Medicaid Services. A Healthcare Common Procedure Coding System Q-Code enables broad and expansive access to patients and providers. Code Q5111 will be effective January 1, 2019, in time for the company's planned first availability of UDENYCA. With the Q-Code in place, Coherus BioSciences is proceeding to apply to CMS for transitional pass-through payment status for hospital outpatient settings. Neulasta is a Registered Trademark of Amgen (AMGN).

AMGN

Amgen

$203.49

1.17 (0.58%)

CHRS

Coherus Biosciences

$10.91

0.15 (1.39%)

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AMGN Amgen
$203.49

1.17 (0.58%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
10/31/18
RBCM
10/31/18
NO CHANGE
Target $182
RBCM
Sector Perform
Amgen price target lowered to $182 from $193 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was "in line" with "safe" expectations, even as the company's core business competition is "slow" to impact sales. MacKay further cites an "astonishing" launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen's Repatha.
10/29/18
PIPR
10/29/18
NO CHANGE
PIPR
Neutral
Piper sees Amgen's Aimovig pressuring Allergan's Botox in near term
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen (AMGN) and Neutral rating on Allergan (AGN) after his firm's Overweight based on feedback from a migraine survey fielded by his firm's partner Spherix Global Insights. The analyst is "struck by the progress" Amgen has made just months into Aimovig's launch, specifically on sales coverage, message delivery and overall credibility with physicians. It appears that Allergan's Botox "could be in for some pressure in the near term at the direct hands" of Amgen's Aimovig, Raymond tells investors in a research note titled "Aiming for Aimovig; New Migraine Survey Indicates Aimovig the Star of the Show." Doctors are projecting peak Aimovig share of 49% and 29% for chronic and episodic patients respectively, which infers peak U.S. revenue for the drug at $3.3B, the analyst says. Further, he notes that of the 98 high volume migraine specialists surveyed, 43% versus 29% agreed with the statement: "I am more likely to prescribe Aimovig over Botox due to access to patient assistance program."
10/25/18
MSCO
10/25/18
NO CHANGE
Target $212
MSCO
Overweight
Repatha list price cut has benefits for Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Amgen announced that it is reducing Repatha's list price by 60%, stating that he believes the new list price of $5,850/year is similar to the current net price for the treatment. He also noted that Amgen management said they anticipate little impact to long-term blended net price, though there could be some volatility in the near-term. Given the current political environment, he sees two key benefits to the strategy, namely that it is "a novel SKU strategy" and second the lower price likely improves a structural headwind since Repatha is largely a Medicare product. Harrison keeps an Overweight rating on Amgen shares.
CHRS Coherus Biosciences
$10.91

0.15 (1.39%)

08/28/18
HCWC
08/28/18
INITIATION
Target $28
HCWC
Buy
Coherus Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Coherus Biosciences (CHRS) with a Buy rating and $28 price target. The analyst expects approval of the company's Udencya in both the U.S. and Europe this year. His confidence level is driven by a positive recommendation from the European Committee for Medicinal Products for Human Use in July for marketing authorization of Udencya, a biosimilar compound targeting febrile neutropenia. Coherus announced that the committee reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU recommendation for approval adds a measure of confidence in support of U.S. approval, Kolbert tells investors in a research note. A year-end approval should position Udencya as the second biosimilar in the $4B U.S. marketplace behind Mylan (MYL), which should be launching its product following approval in June, the analyst adds.
07/27/18
SBSH
07/27/18
NO CHANGE
Target $25
SBSH
Buy
Citi sees Coherus trading to $21-$25 on today's EMA decision
The European Medicines Agency this morning provided a positive opinion on Coherus Biosciences' version of Neulasta, Citi analyst Mohit Bansal tells investors in a research note. This is positive news as it "significantly lowers" regulatory risk for Neulasta in the U.S. as well, Bansal tells investors in a research note. He notes that while the applicant name is not Coherus on the two applications receiving positive opinions today, the drug name trademark "Udenyca" is registered under Coherus and it seems a third party filed the application on Coherus' behalf. The analyst sees the stock trading in the $21-$25 range on the news. He keeps a Buy rating on Coherus Biosciences with a $25 price target. The stock in premarket trading is up 8%, or $1.40, to $19.75.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
05/14/18
MAXM
05/14/18
NO CHANGE
Target $22
MAXM
Buy
Coherus Biosciences price target raised to $22 from $18 at Maxim
Maxim analyst Jason McCarthy raised his price target on Coherus Biosciences to $22 from $18 after the company announced that the FDA has accepted for review the recently re-submitted BLA for CHS-1701, a biosimilar version of Neulasta. The BSUFA date for a decision is November 3, he noted. The analyst keeps his Buy rating on Coherus Biosciences shares.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.